Cargando…

Imaging joint infections using D-methyl-(11)C-methionine PET/MRI: initial experience in humans

PURPOSE: Non-invasive imaging is a key clinical tool for detection and treatment monitoring of infections. Existing clinical imaging techniques are frequently unable to distinguish infection from tumors or sterile inflammation. This challenge is well-illustrated by prosthetic joint infections that o...

Descripción completa

Detalles Bibliográficos
Autores principales: Polvoy, Ilona, Seo, Youngho, Parker, Matthew, Stewart, Megan, Siddiqua, Khadija, Manacsa, Harrison S., Ravanfar, Vahid, Blecha, Joseph, Hope, Thomas A., Vanbrocklin, Henry, Flavell, Robert R., Barry, Jeffrey, Hansen, Erik, Villanueva-Meyer, Javier E., Engel, Joanne, Rosenberg, Oren S., Wilson, David M., Ohliger, Michael A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9399217/
https://www.ncbi.nlm.nih.gov/pubmed/35732972
http://dx.doi.org/10.1007/s00259-022-05858-x
_version_ 1784772474470137856
author Polvoy, Ilona
Seo, Youngho
Parker, Matthew
Stewart, Megan
Siddiqua, Khadija
Manacsa, Harrison S.
Ravanfar, Vahid
Blecha, Joseph
Hope, Thomas A.
Vanbrocklin, Henry
Flavell, Robert R.
Barry, Jeffrey
Hansen, Erik
Villanueva-Meyer, Javier E.
Engel, Joanne
Rosenberg, Oren S.
Wilson, David M.
Ohliger, Michael A.
author_facet Polvoy, Ilona
Seo, Youngho
Parker, Matthew
Stewart, Megan
Siddiqua, Khadija
Manacsa, Harrison S.
Ravanfar, Vahid
Blecha, Joseph
Hope, Thomas A.
Vanbrocklin, Henry
Flavell, Robert R.
Barry, Jeffrey
Hansen, Erik
Villanueva-Meyer, Javier E.
Engel, Joanne
Rosenberg, Oren S.
Wilson, David M.
Ohliger, Michael A.
author_sort Polvoy, Ilona
collection PubMed
description PURPOSE: Non-invasive imaging is a key clinical tool for detection and treatment monitoring of infections. Existing clinical imaging techniques are frequently unable to distinguish infection from tumors or sterile inflammation. This challenge is well-illustrated by prosthetic joint infections that often complicate joint replacements. D-methyl-(11)C-methionine (D-(11)C-Met) is a new bacteria-specific PET radiotracer, based on an amino acid D-enantiomer, that is rapidly incorporated into the bacterial cell wall. In this manuscript, we describe the biodistribution, radiation dosimetry, and initial human experience using D-(11)C-Met in patients with suspected prosthetic joint infections. METHODS: 614.5 ± 100.2 MBq of D-(11)C-Met was synthesized using an automated in-loop radiosynthesis method and administered to six healthy volunteers and five patients with suspected prosthetic joint infection, who were studied by PET/MRI. Time-activity curves were used to calculate residence times for each source organ. Absorbed doses to each organ and body effective doses were calculated using OLINDA/EXM 1.1 with both ICRP 60 and ICRP 103 tissue weighting factors. SUV(max) and SUV(peak) were calculated for volumes of interest (VOIs) in joints with suspected infection, the unaffected contralateral joint, blood pool, and soft tissue background. A two-tissue compartment model was used for kinetic modeling. RESULTS: D-(11)C-Met was well tolerated in all subjects. The tracer showed clearance from both urinary (rapid) and hepatobiliary (slow) pathways as well as low effective doses. Moreover, minimal background was observed in both organs with resident micro-flora and target organs, such as the spine and musculoskeletal system. Additionally, D-(11)C-Met showed increased focal uptake in areas of suspected infection, demonstrated by a significantly higher SUV(max) and SUV(peak) calculated from VOIs of joints with suspected infections compared to the contralateral joints, blood pool, and background (P < 0.01). Furthermore, higher distribution volume and binding potential were observed in suspected infections compared to the unaffected joints. CONCLUSION: D-(11)C-Met has a favorable radiation profile, minimal background uptake, and fast urinary extraction. Furthermore, D-(11)C-Met showed increased uptake in areas of suspected infection, making this a promising approach. Validation in larger clinical trials with a rigorous gold standard is still required. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00259-022-05858-x.
format Online
Article
Text
id pubmed-9399217
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-93992172022-08-25 Imaging joint infections using D-methyl-(11)C-methionine PET/MRI: initial experience in humans Polvoy, Ilona Seo, Youngho Parker, Matthew Stewart, Megan Siddiqua, Khadija Manacsa, Harrison S. Ravanfar, Vahid Blecha, Joseph Hope, Thomas A. Vanbrocklin, Henry Flavell, Robert R. Barry, Jeffrey Hansen, Erik Villanueva-Meyer, Javier E. Engel, Joanne Rosenberg, Oren S. Wilson, David M. Ohliger, Michael A. Eur J Nucl Med Mol Imaging Original Article PURPOSE: Non-invasive imaging is a key clinical tool for detection and treatment monitoring of infections. Existing clinical imaging techniques are frequently unable to distinguish infection from tumors or sterile inflammation. This challenge is well-illustrated by prosthetic joint infections that often complicate joint replacements. D-methyl-(11)C-methionine (D-(11)C-Met) is a new bacteria-specific PET radiotracer, based on an amino acid D-enantiomer, that is rapidly incorporated into the bacterial cell wall. In this manuscript, we describe the biodistribution, radiation dosimetry, and initial human experience using D-(11)C-Met in patients with suspected prosthetic joint infections. METHODS: 614.5 ± 100.2 MBq of D-(11)C-Met was synthesized using an automated in-loop radiosynthesis method and administered to six healthy volunteers and five patients with suspected prosthetic joint infection, who were studied by PET/MRI. Time-activity curves were used to calculate residence times for each source organ. Absorbed doses to each organ and body effective doses were calculated using OLINDA/EXM 1.1 with both ICRP 60 and ICRP 103 tissue weighting factors. SUV(max) and SUV(peak) were calculated for volumes of interest (VOIs) in joints with suspected infection, the unaffected contralateral joint, blood pool, and soft tissue background. A two-tissue compartment model was used for kinetic modeling. RESULTS: D-(11)C-Met was well tolerated in all subjects. The tracer showed clearance from both urinary (rapid) and hepatobiliary (slow) pathways as well as low effective doses. Moreover, minimal background was observed in both organs with resident micro-flora and target organs, such as the spine and musculoskeletal system. Additionally, D-(11)C-Met showed increased focal uptake in areas of suspected infection, demonstrated by a significantly higher SUV(max) and SUV(peak) calculated from VOIs of joints with suspected infections compared to the contralateral joints, blood pool, and background (P < 0.01). Furthermore, higher distribution volume and binding potential were observed in suspected infections compared to the unaffected joints. CONCLUSION: D-(11)C-Met has a favorable radiation profile, minimal background uptake, and fast urinary extraction. Furthermore, D-(11)C-Met showed increased uptake in areas of suspected infection, making this a promising approach. Validation in larger clinical trials with a rigorous gold standard is still required. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00259-022-05858-x. Springer Berlin Heidelberg 2022-06-23 2022 /pmc/articles/PMC9399217/ /pubmed/35732972 http://dx.doi.org/10.1007/s00259-022-05858-x Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Original Article
Polvoy, Ilona
Seo, Youngho
Parker, Matthew
Stewart, Megan
Siddiqua, Khadija
Manacsa, Harrison S.
Ravanfar, Vahid
Blecha, Joseph
Hope, Thomas A.
Vanbrocklin, Henry
Flavell, Robert R.
Barry, Jeffrey
Hansen, Erik
Villanueva-Meyer, Javier E.
Engel, Joanne
Rosenberg, Oren S.
Wilson, David M.
Ohliger, Michael A.
Imaging joint infections using D-methyl-(11)C-methionine PET/MRI: initial experience in humans
title Imaging joint infections using D-methyl-(11)C-methionine PET/MRI: initial experience in humans
title_full Imaging joint infections using D-methyl-(11)C-methionine PET/MRI: initial experience in humans
title_fullStr Imaging joint infections using D-methyl-(11)C-methionine PET/MRI: initial experience in humans
title_full_unstemmed Imaging joint infections using D-methyl-(11)C-methionine PET/MRI: initial experience in humans
title_short Imaging joint infections using D-methyl-(11)C-methionine PET/MRI: initial experience in humans
title_sort imaging joint infections using d-methyl-(11)c-methionine pet/mri: initial experience in humans
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9399217/
https://www.ncbi.nlm.nih.gov/pubmed/35732972
http://dx.doi.org/10.1007/s00259-022-05858-x
work_keys_str_mv AT polvoyilona imagingjointinfectionsusingdmethyl11cmethioninepetmriinitialexperienceinhumans
AT seoyoungho imagingjointinfectionsusingdmethyl11cmethioninepetmriinitialexperienceinhumans
AT parkermatthew imagingjointinfectionsusingdmethyl11cmethioninepetmriinitialexperienceinhumans
AT stewartmegan imagingjointinfectionsusingdmethyl11cmethioninepetmriinitialexperienceinhumans
AT siddiquakhadija imagingjointinfectionsusingdmethyl11cmethioninepetmriinitialexperienceinhumans
AT manacsaharrisons imagingjointinfectionsusingdmethyl11cmethioninepetmriinitialexperienceinhumans
AT ravanfarvahid imagingjointinfectionsusingdmethyl11cmethioninepetmriinitialexperienceinhumans
AT blechajoseph imagingjointinfectionsusingdmethyl11cmethioninepetmriinitialexperienceinhumans
AT hopethomasa imagingjointinfectionsusingdmethyl11cmethioninepetmriinitialexperienceinhumans
AT vanbrocklinhenry imagingjointinfectionsusingdmethyl11cmethioninepetmriinitialexperienceinhumans
AT flavellrobertr imagingjointinfectionsusingdmethyl11cmethioninepetmriinitialexperienceinhumans
AT barryjeffrey imagingjointinfectionsusingdmethyl11cmethioninepetmriinitialexperienceinhumans
AT hansenerik imagingjointinfectionsusingdmethyl11cmethioninepetmriinitialexperienceinhumans
AT villanuevameyerjaviere imagingjointinfectionsusingdmethyl11cmethioninepetmriinitialexperienceinhumans
AT engeljoanne imagingjointinfectionsusingdmethyl11cmethioninepetmriinitialexperienceinhumans
AT rosenbergorens imagingjointinfectionsusingdmethyl11cmethioninepetmriinitialexperienceinhumans
AT wilsondavidm imagingjointinfectionsusingdmethyl11cmethioninepetmriinitialexperienceinhumans
AT ohligermichaela imagingjointinfectionsusingdmethyl11cmethioninepetmriinitialexperienceinhumans